Picture of Medexus Pharmaceuticals logo

MDP Medexus Pharmaceuticals Income Statement

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Annual income statement for Medexus Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

2019
March 31st
R2020
March 31st
2021
March 31st
2022
March 31st
2023
March 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:
fx
Final
FinalFinalFinalFinal
Revenue
Total Revenue25.855.579.776.7108
Cost of Revenue
Gross Profit15.231.14237.960
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses30.361.38191.7100
Operating Profit-4.47-5.79-1.38-157.61
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-4.8-5.54-31.5-3.82-5.04
Provision for Income Taxes
Net Income After Taxes-4.97-4.7-28.3-2.881.22
Net Income Before Extraordinary Items
Net Income-4.97-4.7-28.3-2.881.22
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-4.97-4.7-28.3-2.881.22
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.254-0.117-1.77-0.060.087